The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
Abstract
LRRK2 kinase inhibitors, under development for Parkinson’s disease, have an effect on type II pneumocytes in nonhuman primate lung, suggesting that pulmonary toxicity may be a critical safety liability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,005
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán-Ruı́z, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munain, A. L., Aparicio, S., Gil, A. M., Khan, N., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,405
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., & Dawson, T. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507360102 · Cited by 1,228 · cited 2×
“Themost common LRRK2mutation, G2019S, which is found in the activation loop of the kinase domain, results in increased kinase activity (7, 13), as does the kinase domain I2020T mutation (14).”
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.001 · Cited by 671
Interplay of LRRK2 with chaperone-mediated autophagy
Orenstein, S. J., Kuo, S.-H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I., Cortes, E., Honig, L. S., Dauer, W., Consiglio, A., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3350 · Cited by 588
Kachergus, J., Mata, I. F., Hulihan, M., Taylor, J. P., Lincoln, S., Aasly, J., Gibson, J. M., Ross, O. A., Lynch, T., Wiley, J., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429256 · Cited by 541
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
Cookson, M. R. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2935 · Cited by 539
Tong, Y., Yamaguchi, H., Giaime, E., Boyle, S., Kopan, R., Kelleher, R. J., & Shen, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004676107 · Cited by 501
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity
Gloeckner, C. J., Kinkl, N., Schumacher, A., Braun, R. J., O'Neill, E., Meitinger, T., Kolch, W., Prokisch, H., & Ueffing, M. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi439 · Cited by 477
Cited by
Defects in trafficking bridge Parkinson’s disease pathology and genetics
Abeliovich, A., & Gitler, A. D. (2016) · Nature · doi:10.1038/nature20414 · Cited by 462
Deyaert, E., Wauters, L., Guaitoli, G., Konijnenberg, A., Leemans, M., Terheyden, S., Petrovic, A., Gallardo, R., Nederveen-Schippers, L. M., Athanasopoulos, P. S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01103-4 · Cited by 457
LRRK2 in Parkinson disease: challenges of clinical trials
Tolosa, E., Vila, M., Klein, C., & Rascol, O. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0301-2 · Cited by 438
LRRK2 kinase in Parkinson's disease
Alessi, D. R., & Sammler, E. (2018) · Science · doi:10.1126/science.aar5683 · Cited by 345
Machine translation of cortical activity to text with an encoder–decoder framework
Makin, J. G., Moses, D. A., & Chang, E. F. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0608-8 · Cited by 321
Eguchi, T., Kuwahara, T., Sakurai, M., Komori, T., Fujimoto, T., Ito, G., Yoshimura, S.-I., Harada, A., Fukuda, M., Koike, M., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812196115 · Cited by 313
Fell, M. J., Mirescu, C., Basu, K., Cheewatrakoolpong, B., DeMong, D. E., Ellis, J. M., Hyde, L. A., Lin, Y., Markgraf, C. G., Mei, H., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.227587 · Cited by 305
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 300
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Charvin, D., Medori, R., Hauser, R. A., & Rascol, O. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.136 · Cited by 287
Long-term expansion of alveolar stem cells derived from human iPS cells in organoids
Yamamoto, Y., Gotoh, S., Korogi, Y., Seki, M., Konishi, S., Ikeo, S., Sone, N., Nagasaki, T., Matsumoto, H., Muro, S., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4448 · Cited by 270
LRRK2 links genetic and sporadic Parkinson's disease
Kluss, J. H., Mamais, A., & Cookson, M. R. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180462 · Cited by 221
Glial phagocytic clearance in Parkinson’s disease
Tremblay, M.-E., Cookson, M. R., & Civiero, L. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0314-8 · Cited by 152
Takagawa, T., Kitani, A., Fuss, I., Levine, B., Brant, S. R., Peter, I., Tajima, M., Nakamura, S., & Strober, W. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8162 · Cited by 145
Taylor, M., & Alessi, D. R. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2020.01.001 · Cited by 141
Singh, F., Prescott, A. R., Rosewell, P., Ball, G., Reith, A. D., & Ganley, I. G. (2021) · eLife · doi:10.7554/elife.67604 · Cited by 131
Kuwahara, T., Inoue, K., D’Agati, V. D., Fujimoto, T., Eguchi, T., Saha, S., Wolozin, B., Iwatsubo, T., & Abeliovich, A. (2016) · Scientific Reports · doi:10.1038/srep29945 · Cited by 125
Belluzzi, E., Gonnelli, A., Cirnaru, M.-D., Marte, A., Plotegher, N., Russo, I., Civiero, L., Cogo, S., Carrion, M. P., Franchin, C., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0066-z · Cited by 119
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100
Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner
Shutinoski, B., Hakimi, M., Harmsen, I. E., Lunn, M., Rocha, J., Lengacher, N., Zhou, Y. Y., Khan, J., Nguyen, A., Hake-Volling, Q., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aas9292 · Cited by 96
Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation
Kuwahara, T., Funakawa, K., Komori, T., Sakurai, M., Yoshii, G., Eguchi, T., Fukuda, M., & Iwatsubo, T. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105081 · Cited by 80
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69
Granulin loss of function in human mature brain organoids implicates astrocytes in TDP-43 pathology
de Majo, M., Koontz, M., Marsan, E., Salinas, N., Ramsey, A., Kuo, Y.-M., Seo, K., Li, H., Dräger, N., Leng, K., et al. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.01.012 · Cited by 44
Blundell, P. A., Lu, D., Dell, A., Haslam, S., & Pleass, R. J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901145 · Cited by 29
Endosomal sorting pathways in the pathogenesis of Parkinson's disease
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2020.02.001 · Cited by 25
Human-in-the-loop optimization of visual prosthetic stimulation
Fauvel, T., & Chalk, M. (2021) · doi:10.1101/2021.11.24.469867 · Cited by 15
Human-in-the-loop optimization of visual prosthetic stimulation
Fauvel, T., & Chalk, M. (2022) · Journal of Neural Engineering · doi:10.1088/1741-2552/ac7615 · Cited by 15
Unapanta, A., Shavarebi, F., Porath, J., Shen, Y., Balen, C., Nguyen, A., Tseng, J., Leong, W. S., Liu, M., Lis, P., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105192 · Cited by 11
Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Metadata
- Authors
- Fuji, R. N., Flagella, M., Baca, M., S. Baptista, M. A., Brodbeck, J., Chan, B. K., Fiske, B. K., Honigberg, L., Jubb, A. M., Katavolos, P., Lee, D. W., Lewin-Koh, S.-C., Lin, T., Liu, X., Liu, S., Lyssikatos, J. P., O’Mahony, J., Reichelt, M., Roose-Girma, M., Sheng, Z., Sherer, T., Smith, A., Solon, M., Sweeney, Z. K., Tarrant, J., Urkowitz, A., Warming, S., Yaylaoglu, M., Zhang, S., Zhu, H., Estrada, A. A., & Watts, R. J.
- Venue
- Science Translational Medicine
- Published
- 2015-02-04
- Volume
- 7
- Issue
- 273
- Pages
- 273ra15-273ra15
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2040696002
- Cited by
- 352
- References
- 36
- FWCI
- 17.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.